Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cemsidomide + dexamethasone in relapsed/refractory multiple myeloma
2025-524181-26-00Phase 2Authorised
- Sponsor
- C4 Therapeutics
- Start
- Sep 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 6
01
Overview
Phase 2, open-label, single-arm trial of cemsidomide and dexamethasone in multiple myeloma (MM), sponsored by C4 Therapeutics. Primary endpoint: Overall response rate. Planned start Sep 2026; status: authorised.
02
Drugs
cemsidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2025-524181-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524181-26-00.